Clinical Trials
-
Redefining Clinical Research In The Age Of Genomic Science
11/1/2015
In 2013, TransPoC, Inc. (Translational Proof of Concept) was formed to solve a serious problem: the diminishing number of new drug therapies resulting from oncology research. This problem has become more challenging given the overwhelming volume of genomic data available since the completion of the Human Genome Project in 2003.
-
Compassionate Use Trials Complex, But Improving
11/1/2015
Expanded access (compassionate use) clinical trials aren’t as straightforward as they seem, and applications to expand access for cannabinoid drug trials are even more complicated.
-
How Much Transparency Is Too Much With Clinical Trials?
11/1/2015
There is a growing movement by some researchers and regulators to increase disclosure of clinical trial results.
-
Genentech Pushes The Clinical Trial Envelope
10/1/2015
Having spent more than 11 years at Genentech, Joling Mew has heard a lot of industry discussion about patient-centric trials. Mew is development excellence leader in product development and also works closely with the Strategic Innovation Group.
-
Combination Cancer Immunotherapy: A 2015 Update
9/1/2015
What a difference a year makes. Last year, beginning in September, we ran a series that addressed the challenges and opportunities of using new agents to rally the immune system against cancer. In most cases, we were talking about...
-
A Behind-The-Scenes Look At The Patient Clinical Trial Experience
9/1/2015
“When I got ill, it was completely by surprise,” says Dr. Jan Vesseur. The former general practitioner who now works as a civil servant for the Netherlands Ministry of Health was on a skiing trip in France when a fall forever changed his life. “My daughter, also a doctor, was with me,” he recalls. “The fall was very soft, and we couldn’t believe it was anything other than some low-back pain.”
-
Remote Clinical Trials: A Goal Just Over The Horizon
5/4/2015
People don’t think twice to pay bills on a smartphone, share experiences on social media, and even monitor sleep habits on wearable activity trackers. But when it comes to participating in a study to test a new therapy or medical device, we might as well be standing in line at the bank to deposit a paper check.
-
Drug Development In The Age Of Social Media
5/4/2015
A young, energetic biotech; a promising drug with encouraging Phase 2 data; a young patient population; a disease target for which there is no successful treatment.
-
Building A Patient Advocacy, Diversity, And Engagement Focus At BMS
3/31/2015
When Lori Abrams was named director of advocacy, diversity, and patient engagement for Global Development Operations at Bristol-Myers Squibb (BMS), she had no one to manage. In fact, her first assignment was to create the department she would oversee. “The first thing I realized was there didn’t seem to be many such departments for me to benchmark against,” she notes. “I went around to a lot of pharma companies trying to find someone to talk to, but an advocacy position focused on clinical trials just didn’t seem to exist.”
-
The Rise Of Digiceuticals – Can You Afford To Not Get Involved?
2/25/2015
When Heather Bell hears the term digiceuticals, she can’t help but think about transformation. “I think that mobile health [the use of smartphones, tablets, and other mobile computing devices to record patient information] has the potential to be profoundly transformative for healthcare,” says Bell, formerly AstraZeneca’s VP of program management in IT/operations and now Sanofi’s VP of corporate strategy and emerging opportunities.